Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram.
SEER database
biliary neuroendocrine neoplasms
nomogram
prognostic factors
survival rate
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
01
2021
accepted:
05
07
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
6
8
2021
Statut:
epublish
Résumé
For this study, we explored the prognostic profiles of biliary neuroendocrine neoplasms (NENs) patients and identified factors related to prognosis. Further, we developed and validated an effective nomogram to predict the overall survival (OS) of individual patients with biliary NENs. We included a total of 446 biliary NENs patients from the SEER database. We used Kaplan-Meier curves to determine survival time. We employed univariate and multivariate Cox analyses to estimate hazard ratios to identify prognostic factors. We constructed a predictive nomogram based on the results of the multivariate analyses. In addition, we included 28 biliary NENs cases from our center as an external validation cohort. The median survival time of biliary NENs from the SEER database was 31 months, and the value of gallbladder NENs (23 months) was significantly shorter than that of the bile duct (45 months) and ampulla of Vater (33.5 months, p=0.023). Multivariate Cox analyses indicated that age, tumor size, pathological classification, SEER stage, and surgery were independent variables associated with survival. The constructed prognostic nomogram demonstrated good calibration and discrimination C-index values of 0.783 and 0.795 in the training and validation dataset, respectively. Age, tumor size, pathological classification, SEER stage, and surgery were predictors for the survival of biliary NENs. We developed a nomogram that could determine the 3-year and 5-year OS rates. Through validation of our central database, the novel nomogram is a useful tool for clinicians in estimating individual survival among biliary NENs patients.
Sections du résumé
BACKGROUND
BACKGROUND
For this study, we explored the prognostic profiles of biliary neuroendocrine neoplasms (NENs) patients and identified factors related to prognosis. Further, we developed and validated an effective nomogram to predict the overall survival (OS) of individual patients with biliary NENs.
METHODS
METHODS
We included a total of 446 biliary NENs patients from the SEER database. We used Kaplan-Meier curves to determine survival time. We employed univariate and multivariate Cox analyses to estimate hazard ratios to identify prognostic factors. We constructed a predictive nomogram based on the results of the multivariate analyses. In addition, we included 28 biliary NENs cases from our center as an external validation cohort.
RESULTS
RESULTS
The median survival time of biliary NENs from the SEER database was 31 months, and the value of gallbladder NENs (23 months) was significantly shorter than that of the bile duct (45 months) and ampulla of Vater (33.5 months, p=0.023). Multivariate Cox analyses indicated that age, tumor size, pathological classification, SEER stage, and surgery were independent variables associated with survival. The constructed prognostic nomogram demonstrated good calibration and discrimination C-index values of 0.783 and 0.795 in the training and validation dataset, respectively.
CONCLUSION
CONCLUSIONS
Age, tumor size, pathological classification, SEER stage, and surgery were predictors for the survival of biliary NENs. We developed a nomogram that could determine the 3-year and 5-year OS rates. Through validation of our central database, the novel nomogram is a useful tool for clinicians in estimating individual survival among biliary NENs patients.
Identifiants
pubmed: 34350109
doi: 10.3389/fonc.2021.654439
pmc: PMC8327779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
654439Informations de copyright
Copyright © 2021 Zhou, Jiang, Chen, Yin, Dong, Zhao, Han and He.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
J Gastroenterol. 2020 May;55(5):543-552
pubmed: 31858231
J Clin Med. 2021 Apr 17;10(8):
pubmed: 33920514
Endocr Rev. 2019 Apr 1;40(2):506-536
pubmed: 30657883
J Cancer. 2019 Oct 15;10(24):5944-5954
pubmed: 31762804
Semin Nucl Med. 2020 Sep;50(5):447-464
pubmed: 32768008
Neuroendocrinology. 2010;92(3):143-57
pubmed: 20733279
ESMO Open. 2021 Jun;6(3):100119
pubmed: 33901869
Ann Surg. 2014 Feb;259(2):204-12
pubmed: 23673766
Front Oncol. 2019 Feb 05;9:38
pubmed: 30805307
Ann Surg. 2019 Sep 24;:
pubmed: 31567347
Pancreas. 2019 May/Jun;48(5):613-621
pubmed: 31091206
Scand J Gastroenterol. 2017 Apr;52(4):437-441
pubmed: 27924650
Surgery. 2016 Aug;160(2):525-6
pubmed: 26873297
Nat Rev Endocrinol. 2020 Oct;16(10):590-607
pubmed: 32839579
Hum Pathol. 2005 Jul;36(7):732-40
pubmed: 16084941
Pancreas. 2010 Aug;39(6):707-12
pubmed: 20664470
J Gastrointest Surg. 2014 Feb;18(2):354-62
pubmed: 24114680
Virchows Arch. 2010 Jun;456(6):595-7
pubmed: 20422210
Dig Liver Dis. 2011 Dec;43(12):965-70
pubmed: 21856258
Pathol Oncol Res. 2014 Oct;20(4):765-75
pubmed: 24917351
World J Surg Oncol. 2019 Mar 22;17(1):55
pubmed: 30902091
Oncologist. 2020 Apr;25(4):e659-e667
pubmed: 32297441
Endocr Connect. 2019 Sep;8(9):1273-1281
pubmed: 31398710
J Cancer Res Clin Oncol. 2021 May 13;:
pubmed: 33983461
Arch Pathol Lab Med. 2016 Oct;140(10):1157-62
pubmed: 27684986
Neuroendocrinology. 2016;103(2):117-8
pubmed: 26731186
Yonsei Med J. 2012 Sep;53(5):944-51
pubmed: 22869477
J Clin Med. 2020 Aug 03;9(8):
pubmed: 32756529
Cancer Manag Res. 2020 Feb 26;12:1437-1446
pubmed: 32161496
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Clin Cancer Res. 2019 Jan 15;25(2):584-594
pubmed: 30397175
Ann Surg Oncol. 2019 Oct;26(11):3577-3585
pubmed: 31102094
Endocr Rev. 2020 Apr 1;41(2):
pubmed: 31555796
Pancreatology. 2016 Jan-Feb;16(1):99-105
pubmed: 26718527
J Clin Gastroenterol. 2010 Nov-Dec;44(10):687-95
pubmed: 20375728
BMC Cancer. 2020 Sep 9;20(1):865
pubmed: 32907602